SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending amid a significant price surge, with investors highlighting the launch of a new Grayscale Zcash ETF as a key catalyst for ongoing momentum and liquidity. While many traders express bullish sentiment regarding its privacy-focused technology and potential to surpass other major cryptocurrencies, others remain cautious of potential volatility, profit-taking, or regulatory risks.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

The conversation surrounding HYPE centers on excitement over its fee-burning mechanism and recent developments, including speculation about potential U.S. market access via Kraken and the launch of prediction markets. Traders are debating the asset's long-term valuation, with many citing its revenue-sharing model and growth potential, though some remain cautious about volatility and the impact of upcoming token unlocks.

Hyperliquid Strategies, Inc. is a holding and operating company, which engages in the business of crypto asset management. The firm operates as a digital asset treasury company which focuses on the Hyperliquid ecosystem. The company was founded on July 2, 2025 and is headquartered in New York, NY.

Hyperliquid Strategies Inc.

PURR is attracting attention as traders focus on its strong balance sheet, which includes a substantial Hyperliquid (HYPE) treasury, and the company's aggressive stock buyback programs. The stock is currently experiencing high volatility driven by speculation around token price action, upcoming earnings, and the broader institutional adoption of crypto-linked equities.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is trending as traders speculate on its potential for a significant price rally, often drawing parallels to recent movements in Zcash and highlighting its perceived scarcity and utility as a privacy-focused asset. The conversation is heavily driven by community sentiment regarding technical chart patterns and the anticipation of broader altcoin market momentum.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is facing downward price pressure and increased volatility amid broader market concerns over geopolitical developments and shifting rate-hike expectations, leading to a divide among traders regarding the asset's near-term direction. While some remain bullish on long-term institutional adoption and tokenization catalysts, others are expressing skepticism, citing weak price action relative to Bitcoin and potential further corrections.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

UniSwap is trending as the community anticipates a major governance proposal involving a massive token burn and the activation of a fee switch. Traders are optimistic that these developments will reduce supply and generate sustainable protocol revenue, fueling debate over the token's long-term utility and price potential.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

The community sentiment regarding AppLovin is divided, with bullish investors emphasizing the company's strong fundamentals and cash flow as grounds for a rebound, while others express frustration over intraday price volatility and accuse market makers of manipulating the stock. Many participants view the current price level as an accumulation opportunity, targeting a significant recovery despite ongoing uncertainty and technical pressure.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending as traders speculate on positive catalysts heading into the second quarter earnings release, including strong sales momentum for its lead drug YARTEMLEA and potential milestone payments from Novo Nordisk. Discussion is heavily focused on the company's improved financial health, institutional interest, and the expectation of a short squeeze due to high short interest and limited share availability.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop shares are currently trading in a tight, low-volume consolidation range as traders debate the company's future following the conclusion of a significant convertible note exchange. While some investors express frustration over a perceived lack of clear communication from leadership and stagnant price action, others remain bullish on the potential for future share buybacks and the firm's overall financial position.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is experiencing increased investor optimism driven by significant insider buying, including a recent $1 million open-market purchase by the CEO and other board members, which has bolstered sentiment following an earnings beat. While some traders express frustration with the stock's long-term performance and dividend, others view the current price level as an undervalued opportunity for a turnaround, particularly as the company focuses on oncology, weight-loss drug pipelines, and continued dividend distributions.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioNTech shares are experiencing volatility following a weak quarterly revenue report and the surprise announcement that co-founders Ugur Sahin and Ozlem Tureci will depart by year-end to launch a new venture, leading to investor uncertainty despite the company's large cash reserves and extensive oncology pipeline.

BNTX Ends Colorectal Cancer Immunotherapy Study, Stock Down

BioNTech discontinues a phase II colorectal cancer study after updated data show an efficacy imbalance, while a pancreatic cancer study continues.

BNTX Stock On Track For Worst Day Since March After Cancer Vaccine Trial Halt — BMO Capital Terms It ‘Clear Setback’

Equity

BioNTech said on Friday that it and its partner, Genentech, a Roche unit, are ending the mid-stage study of autogene cevumeran, used alone after surgery, in certain high-risk stage II or III colorectal cancer patients. 


Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Pfizer Inc. (NYSE: PFE, Pfizer) and BioNTech SE (Nasdaq: BNTX, BioNTech) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies 2026-2027 COVID-19 vaccine formula targeting the XFG variant (COMIRNATY XFG...

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology   New York, NY – August 26, 2026 – Market News Updates News Commentary – If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The basic idea is surprisingly straightforward: instead of […]
The post A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity appeared first on Financial News Media.

Should You Buy Moderna Stock Following Its Cancer Breakthrough?

MRNA's cancer therapy scores a phase III win, strengthening its mRNA platform, while pipeline risks and competition remain key concerns.

ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’

ARCT stock was most recently buoyed by positive late-stage results from Merck and Moderna on their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.


SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology

Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.

ARCT Defies mRNA Selloff And Extends Rally As Moderna, BioNTech Shares Pull Back

The rally around MRNA names began on Wednesday after Merck and Moderna reported positive late-stage results for their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.


Is Cancer the Next Breakthrough for Moderna After COVID-19?

MRNA's cancer therapy scores a first phase III win, fueling hopes its mRNA platform can drive growth beyond COVID-19 vaccines.

Moderna Is Now S&P 500’s No. 2 Stock This Year — Wall Street, Jim Cramer And Elon Musk Cheer Cancer Vaccine Breakthrough

The breakthrough sparked a broad biotech rally, lifting Merck, BioNTech, Arcturus, cancer-treatment developers, gene-editing stocks and biotech ETFs.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Bearish Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Current Price	$103.76
Prev Close	$102.88
Open	$102.78
Dividend Yield	0.00%
50-Day Moving Average	$96.51
Beta	0.85
Avg. Volume	1.81M
PE Ratio	-13.22

52-Week High	$124.00
52-Week Low	$79.52
Market Capitalization	$26.06B
EPS (Annual)	-$5.30
Price to Book	1.28
Revenue Per Employee	$414,872.02

Feed

News

Sentiment

Earnings

Fundamentals

Info

BNTX Fundamentals